Recognizing HRS-AKI in Time to Act: Opportunities to Change the Course With Earlier Detection

Hepatorenal syndrome-acute kidney injury (HRS-AKI) remains one of the most serious complications of advanced liver disease, often developing rapidly and with high mortality if not promptly recognized. Early detection and accurate diagnosis are critical to improve outcomes and guiding effective intervention.

In Part 1 of this two-part video podcast series, two nationally recognized HRS-AKI experts discuss how to spot early signs of HRS-AKI, recognize precipitating factors, and apply diagnostic criteria to support faster intervention. You will gain practical insights into identifying at-risk patients, recognizing clinical indicators, and improving diagnostic accuracy for this critical condition.

AGENDA

• Recognize the causes, risk factors, and precipitating factors of hepatorenal syndrome-acute kidney injury (HRS-AKI)
• Identify clinical indictors and laboratory findings associated with the diagnostic criteria for HRS-AKI to support early diagnosis and intervention

*PRIME® has identified, reviewed, and mitigated all relevant financial relationships that speakers, authors, course directors, planners, peer reviewers, or relevant staff disclose prior to the delivery of any educational activity.

The following individuals have identified relevant financial relationships with ineligible companies to disclose:

• Todd Frederick, MD (Speaker)
  
  Advisory Board or Panel – Ipsen, Madrigal, Mallinckrodt
  Consultant – Mallinckrodt, Miromatrix
  Grants / Research Support – AstraZeneca, Mallinckrodt, River 2 Renal, Salix
  Speakers Bureau or other Promotional Education – Madrigal
  Stock / Shareholder (self- managed) – Madrigal
  The relationships reported above are related to the following therapeutic area: Gastroenterology
• Kristi Kay Orbaugh, RN, MSN, RNP, AOCN (Planner)
  
  Speakers Bureau or other Promotional Education – Astellas, AstraZeneca, Bristol-Myers Squibb, CTI, Coherus, DSI, Dova, Eli Lilly and Company, Gilead Sciences, Morphosys, Pfizer
  The relationships reported above are related to the following therapeutic area: Oncology

The following individuals have no relevant financial relationships with ineligible companies to disclose:

• Amanda Chaney, DNP, APRN, FAANP, AF-AASLD (Speaker)
• Annette Sophin, MSMM, PA-C (Reviewer)
• Abimbola Farinde, PhD, PharmD (Planner)

All PRIME® staff participating in planning and content development have no relevant financial relationships with ineligible companies to disclose.